Abstract: Disclosed are compounds having the structure: wherein Z1 is NR4, O, or S; Z2 is CR7 or N; n is 1 to 5; R1 is —H, halogen, —O-alkyl, or together with R2 forms —O—CH2—O—; R2 is —H, —OH, —O-alkyl, —O-alkyl-aryl, —S-alkyl, —S-alkyl-aryl, or together with R1 or R3 forms —O—CH2—O—; R3 is —H, —O-alkyl or together with R2 forms —O—CH2—O—; R4 is H or alkyl; R5 and R6 are each independently H, alkyl, alkenyl, alkynyl or NR5R6 together form a substituted or unsubstituted heterocycle, wherein the heterocycle may be monocyclic or bicyclic, R7 is H or alkyl; wherein R1 is F, when R2 is —O-(n-propyl) or when at least one of R5 or R6 is H, and wherein the compound is other than a compound where Z1 is NR4 and R1, R2, R3, and R8 are H; n is 2, R1 is halogen, R2 is —OCH3, R3 is —H, R4 is —H, and R5 and R6 are both methyl; n is 2, R1 is —F, R2 is —OCH3, R3 is —H, R4 is —H, and NR5R6 together are —N-pyrrolidine; n is 2, R1 and R2 together forms —O—CH2—O—, R3 is —H, R4 is —H, and R5 and R6 are both methyl; and n is 2, R1

Abstract: The present invention provides method of treating a subject afflicted with a movement disorder, comprising administering to the subject a compound having the structure: wherein R1 is —(C2-C12 alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl); R2 is H, halogen, —NO2, —CN, —CF3, —CF2H, —CH2OCH3, —CF2CH3, —CF2OCH3, -(alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl), -(cycloalkylalkyl), -(heteroalkyl), -(heterocycle), -(heterocycloalkyl), -(aryl), -(heteroaryl), -(hydroxyalkyl), -(haloalkyl), -(alkylaryl), —OH, —O-(alkyl), —O-(alkenyl), —O-(alkynyl), —O-(haloalkyl), —O-(aryl), —O-(heteroaryl), —OCF3, SH, —S-(alkyl), —S-(alkenyl), —S-(alkynyl), —S-(aryl), —S-(heteroaryl), —NH2, —NH-(alkyl), —NH-(alkenyl), —NH-(alkynyl), —N-(alkyl)2, NH-(aryl), —NH-(heteroaryl), —CO2H, —CO2-(alkyl), —C(O)—NH2, —C(O)—NH-(alkyl), —C(O)—NH-(aryl), —SO2CH3 or —Si(CH3)3; R3 is —OCH3, —OCH2CH3, —F or —Cl; and R4 is —OCH3, —OCH2CH3 or —SCH3; wherein when R1 is —CH2CH3, R3 is —OCH3, and R4 is —OCH3, then R2 is other than H, —CH3, —CH2CH3, —

Abstract: The present invention provides a compound having the structure: wherein D, E and F are each independently NR1, CR2R3 or CR6R7, wherein one of D, E and F is NR1 and the remaining two are CR2R3 or CR6R7, wherein R1 is H or -(alkyl), and wherein R2, R3, R6 and R7 are each independently H, -(alkyl), -(alkenyl), -(alkynyl), -cycloalkyl, -alkylcycloalkyl, -aryl, heteroaryl or -alkylaryl; X1 is C or N; X2 is O, S, N, NR14 or CR15, wherein R14 is H, -(alkyl) or -cycloalkyl, wherein R15 is H, -(alkyl) or -cycloalkyl, and wherein X2 is other than N when X1 is N; ? and ? represent a bond that is present or absent, and wherein either ? or ? is present, wherein when ? is present, then X1 is C and X2 is O, S or NR14, or when ? is present, then X1 is N and X2 is N or CR15; R4, R5, R8 and R9 are each independently H, -(alkyl), -(alkenyl), -(alkynyl), -cycloalkyl, -alkylcycloalkyl, -aryl, heteroaryl, -alkylaryl, —OH, —O(alkyl), —OAc, —S(alkyl), —NH2, —NH(alkyl), —N(alkyl)2, —COOH, —CO2(alkyl), —CONH2, —CONH(alk

Abstract: Methylene-cycloalkylacetate compounds and derivatives thereof and their use in methods for treatment of neurotropic conditions.